The DESTINY-Breast04 trial demonstrated that the novel antibody-drug conjugate (ADC), trastuzumab deruxtecan, exhibits significant therapeutic efficacy in HER2-low advanced breast cancer [10], likely due to its unique bystander effect [11]. This evidence concerns the gene ERBB2 and breast carcinoma.